Related references
Note: Only part of the references are listed.Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)
Messoud Ashina et al.
CEPHALALGIA (2020)
From transformation to chronification of migraine: pathophysiological and clinical aspects
M. Torres-Ferrus et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Pharmacologic Characterization of ALD403, a Potent Neutralizing Humanized Monoclonal Antibody Against the Calcitonin Gene-Related Peptide
Leon F. Garcia-Martinez et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2020)
Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2
Richard B. Lipton et al.
NEUROLOGY (2020)
Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study
Stephen Silberstein et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study
Timothy R. Smith et al.
CLINICAL THERAPEUTICS (2020)
Population pharmacokinetic and exposure-response analysis of eptinezumab in the treatment of episodic and chronic migraine
Brian Baker et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2020)
Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition
Hans-Christoph Diener et al.
CEPHALALGIA (2019)
Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial
David W. Dodick et al.
CEPHALALGIA (2019)
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition
Jes Olesen
CEPHALALGIA (2018)
A practical guide to understanding Kaplan-Meier curves
Jason T. Rich et al.
OTOLARYNGOLOGY-HEAD AND NECK SURGERY (2010)